Neurocrine Biosciences | NBIX - الأصول





الأصول تغيير تاريخ
AbbVie USD 133.96B 62M 2025-12
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Pfizer USD 207.62B 542M 2026-03
Prothena USD 326.8M 25.82M 2025-12
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Repligen USD 2.95B 25.99M 2025-12
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03
Xoma USD 263.15M 39.7M 2025-09